Phase 1 study of chidamide in combination with venetoclax, azacitidine, aclarubicin, cytarabine and G-CSF for refractory/relapsed acute myeloid leukemia: clinical safety, efficacy, and correlative analysis

BackgroundRelapsed or refractory AML (R/R-AML) remains a particularly adverse population necessitating improved therapeutic strategies. In this phase 1 study, we evaluated the efficacy and safety of chidamide, azacitidine, cytarabine, aclarubicin and granulocyte colony-stimulating factor (CACAG) in...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Yanan Wen, Jingjing Yang, Xiawei Zhang, Qingyang Liu, Wenjing Gao, Lili Dong, Weijia Zhao, Sai Huang, Daihong Liu, Yu Jing, Liping Dou
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2025-12-01
Edice:	Frontiers in Immunology
Témata:	acute myeloid leukemia relapsed refractory salvage regimen venetoclax
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1698710/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!